diversification

Among recent megamergers only AbbVie-Allergan looks like a winner: analyst
Among recent megamergers only AbbVie-Allergan looks like a winner: analyst
Fierce Pharma
AbbVie
Allergan
M&A
diversification
Flag link:
5 reasons AbbVie bought Allergan, and why they may not be enough
5 reasons AbbVie bought Allergan, and why they may not be enough
Biopharma Dive
AbbVie
Allergan
M&A
Humira
Botox
cash
diversification
Flag link:
J&J Finally Returning to Its Roots in Diversity?
J&J Finally Returning to Its Roots in Diversity?
Yahoo/GuruFocus
JNJ
diversification
Flag link:
Will Sanofi (SNY) Stock Advance Today on Diversification, Acquisitions Strategy?
Will Sanofi (SNY) Stock Advance Today on Diversification, Acquisitions Strategy?
TheStreet.com
Sanofi
diversification
M&A
Flag link:
AbbVie’s Gonzalez Seeks Quick Diversity With Shire Offer
AbbVie’s Gonzalez Seeks Quick Diversity With Shire Offer
Bloomberg
AbbVie
Richard Gonzalez
Shire
M&A
diversification
Flag link:
Interview: Ligand Management Says Product Diversification Reduces Its Risk
Interview: Ligand Management Says Product Diversification Reduces Its Risk
Seeking Alpha
Ligand Pharmaceuticals
diversification
Flag link:
Big Pharma Diversification: A Winning Model or Recipe for Disaster?
Big Pharma Diversification: A Winning Model or Recipe for Disaster?
Motley Fool
Big Pharma
diversification
Merck
Eli Lilly
AbbVie
Abbott Laboratories
Pfizer
Flag link:
Is Concentration Better Than Diversification in Pharma?
Is Concentration Better Than Diversification in Pharma?
Motley Fool
diversification
concentration
AbbVie
Abbott Labs
Pfizer
Zoetis
spinoffs
Flag link:
Drugmaker Endo Diversifies Its Product Lineup Through Acquisitions
Drugmaker Endo Diversifies Its Product Lineup Through Acquisitions
Investors.com
Endo
diversification
Flag link:
Sanofi-Aventis: Rumored $20 Billion Swoop Could Be About Diversification
Sanofi-Aventis: Rumored $20 Billion Swoop Could Be About Diversification
Seeking Alpha
Sanofi
diversification
M&A
Biogen Idec
Genzyme
Covidien
Celgene
Shire
Gilead Sciences
Eli Lilly
Bristol-Myers Squibb
Hospira
Cardinal Health
Flag link:
Glaxo CEO: Time to diversify, help poor countries
Glaxo CEO: Time to diversify, help poor countries
Yahoo/AP
GSK
Pharma CEOs
Andrew Witty
diversification
Flag link:
GlaxoSmithKline takes 19 percent stake in South Africa's Aspen as it continues to diversify
GlaxoSmithKline takes 19 percent stake in South Africa's Aspen as it continues to diversify
Yahoo/AP
Aspen
M&A
GSK
diversification
South Africa
Flag link: